Safety and Immunologic Activity of Multiple Infusions of APN401

Trial Profile

Safety and Immunologic Activity of Multiple Infusions of APN401

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs APN 401 (Primary)
  • Indications Colorectal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2018 Results (n=16) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2018 According to an Apeiron Biologics media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
    • 29 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top